HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Raises Price Target to $215

HC Wainwright & Co. analyst Andrew S. Fein maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $192 to $215.